Europe Pharmaceutical Packaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Europe Pharmaceutical Packaging Market Trends and Insights

Growth of Biologics and Injectable Therapies

Biologics accounted for more than 30% of new molecular entities approved by the European Medicines Agency in 2024, elevating demand for parenteral containers with low extractables and tight dimensional tolerances. SCHOTT Pharma reported EUR 2.095 billion (USD 2.30 billion) in fiscal 2024 revenue, 78% of which came from drug containment solutions, including Type I borosilicate vials and cyclic olefin polymer cartridges.^{[1]SCHOTT Pharma, “Annual Report 2024,” schott.com} West Pharmaceutical Services derived USD 1.98 billion from proprietary components, including NovaPure stoppers and Daikyo Crystal Zenith syringes in the nine months to September 2024. Stevanato Group grew its first-half 2024 revenue 11.6% year over year, driven by EZ-fill vials and the Nexa autoinjector platform. A September 2024 alliance among Gerresheimer, Stevanato, and SCHOTT Pharma is expected to harmonize ready-to-fill specifications, potentially reducing qualification timelines for biosimilars, particularly in Poland and Italy, where contract manufacturing growth is strongest.

Stringent EU Serialization Mandates

The Falsified Medicines Directive requires every prescription pack distributed in the European Union to carry a unique identifier and a tamper-evident device, generating a EUR 1.2 billion aftermarket for serialized labels, 2D barcodes, and NFC-equipped cartons through 2026.^{[2]European Medicines Agency, “Falsified Medicines Directive,” ema.europa.eu} Schreiner MediPharm has expanded its NFC label portfolio to support authentication and patient engagement use cases. CCL Industries reported CAD 5.1 billion (USD 3.75 billion) revenue for the first nine months of 2024, with healthcare and specialty labels benefiting from aggregation upgrades. The United Kingdom has mirrored EU serialization rules post-Brexit, compelling label converters to deliver interoperable solutions for pan-European supply chains.

Adoption of NFC-Enabled Smart Labels for Anti-Counterfeiting

Near-field communication labels embed encrypted chips that confirm product provenance, register custody transfers, and deliver patient-facing content. AptarGroup’s Pharma segment earned USD 445 million in Q3 2024, supported by connected inhalers and autoinjectors linked to cloud-based medication-adherence dashboards. German and French payers, who are piloting outcomes-based reimbursement, now request adherence data harvested via smart packs for biologics priced above EUR 500 per dose. As a result, pharmaceutical brands are integrating IoT-ready NFC tags during secondary-pack design stages rather than retrofitting late in the cycle.

Expansion of Temperature-Controlled Mail-Order Pharmacies

Direct-to-patient distribution is scaling as advanced therapy medicinal products receive EMA guidance for home administration. UPS Healthcare invested USD 500 million in GDP-certified hubs across Poland and the Netherlands during 2024, raising European cold-chain capacity by 30%. DHL Supply Chain inaugurated automated cold stores in Germany and Spain that monitor real-time temperature excursions via IoT-enabled shippers.^{[3]UPS Healthcare, “European Cold-Chain Expansion,” ups.com} Redcare Pharmacy commissioned a 25,000-square-meter fulfillment center in Germany, capable of handling biologics and over-the-counter items at multiple temperatures. Visibility into last-mile integrity is reducing reimbursement cycles as payers track therapy outcomes in real-time.

Volatility in Pharmaceutical-Grade Raw Material Prices

Borosilicate glass tubing and cyclic olefin copolymer resins climbed 18-22% in 2024 as European energy costs surged. Continuous glass furnaces require an operating temperature of 1,500 °C, anchoring producers to natural-gas inputs that remain vulnerable to geopolitical shocks. West Pharmaceutical Services now secures its supply with multi-year resin contracts to protect Daikyo Crystal Zenith components from spot-price fluctuations. Elevated input costs have accelerated material-substitution studies involving cyclic olefin polymer and polyethylene terephthalate glycol; however, these alternatives require extensive stability data before EMA approval.

Capacity Bottlenecks for Pharma-Grade Molded Glass Vials

COVID-19 vaccination campaigns and biosimilar launches are expected to stress European molded-glass capacity through mid-2024, with lead times peaking at 28 weeks before easing to 16-20 weeks in Q4 2024. SCHOTT Pharma is installing new furnaces in Hungary and Serbia, which will enable the production of 1 billion vials per year by 2026. Nonetheless, the 18-to 24-month commissioning window for ISO 15378-certified lines keeps supply tight, sustaining pricing power for incumbents. Pharmaceutical firms, therefore, prioritize ready-to-fill platforms that shorten fill-finish cycles and lower particulate risks.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Material Type: Biopolymers Gain Momentum as PPWR Deadlines Near

Plastics dominated the Europe pharmaceutical packaging market with a 52.03% share in 2025, led by polyethylene terephthalate bottles and polypropylene blister films. Glass remained second in value, owing to Type I borosilicate vials and cartridges, a segment fortified by EUR 1.5 billion (USD 1.65 billion) in furnace investments from Gerresheimer, Schott Pharma, and SGD Pharma between 2023 and 2027. Biopolymers and composite materials are projected to grow at a 6.86% CAGR, driven by brand owners seeking to meet PPWR recycled-content requirements without compromising barrier properties. Amcor and Nolato are qualifying polylactic and polyhydroxyalkanoate resins for non-contact layers that still meet the ISO 15378 process validation thresholds.

Regulatory hurdles slow the uptake of biopolymers in primary containers, yet converters with scale can amortize validation costs, creating a two-tier supplier landscape. As PPWR enforcement tightens after 2028, growth in plastics for oral-solid dosage formats will moderate, while Glass and cyclic olefin polymers will retain their premium status in high-value biologics.

By Packaging Type: Primary Containers Capture Biologics Premium

Primary formats are expected to account for 62.10% of the Europe pharmaceutical packaging market size in 2025 and are projected to rise at a 6.58% CAGR through 2031. Bottles for tablets remain the largest sub-segment, but their growth lags as injectables and inhalables gain share. Pre-fillable syringes and cartridges underpin West Pharmaceutical Services’ USD 1.98 billion proprietary-components revenue, highlighting the margin leverage embedded in drug-delivery systems. Vials and ampules face intermittent supply constraints despite the introduction of new capacity in Hungary and Serbia.

Secondary packaging, which accounts for 30-35% of spending, grows in tandem with serialization and NFC adoption, as evidenced by CCL Industries’ healthcare-label revenue uptick. Tertiary corrugated packs hold the balance, aided by e-commerce distribution for chronic-disease therapies. The underlying shift concentrates value creation in primary packs where regulatory moats and technical complexity remain highest.

By Technology: Smart Solutions Outpace Conventional Formats

Conventional designs still accounted for 45.05% of 2025 revenue, but smart and connected formats are expected to compound at 7.55% through 2031 as serialization, anti-counterfeiting, and adherence monitoring converge. Schreiner MediPharm’s NFC labels, already embedded in oncology cartons, authenticate origin and push dosing reminders to smartphones. 

AptarGroup’s connected inhalers stream sensor data to cloud dashboards, underpinning its USD 445 million Q3 2024 Pharma turnover. Aseptic-sterile technologies expand in lockstep with the growth of biologics, while recyclable-ready designs accelerate as PPWR milestones near.

By End User: Outsourced Capacity Accelerates Among Mid-Tier Biotechs

In-house pharmaceutical plants accounted for 54.40% of demand in 2025. Yet, contract manufacturing organizations are attracting investment, growing at a 6.36% CAGR, as mid-sized biotechs race to market without building costly fill-finish lines. Almac Group’s GBP 65 million (USD 81.9 million) packaging hub in the United Kingdom offers serialization and cold-chain services for late-phase trials. 

Sandoz’s PLN 171 million (USD 43 million) center in Poland produces 4 billion serialized blister packs annually. Hospitals and clinics, the smallest segment, increasingly order unit-dose packs to curb medication error risks. The Europe pharmaceutical packaging market, therefore, splits between vertically integrated big pharma and outsourcing-oriented biotech innovators.

Geography Analysis

Germany generated 22.30% of the European pharmaceutical packaging market revenue in 2025, anchored by clustered glass-vial makers such as Gerresheimer and Schott Pharma, whose combined 2024 sales surpassed USD 4 billion. Energy-price volatility elevated input costs, leading converters to favor ready-to-fill formats that reduce furnace runtime and speed customer validation.

Poland is poised for the fastest 7.72% CAGR through 2031, as pharmaceutical companies establish greenfield aseptic and serialization-ready facilities, supported by government R&D incentives. Sandoz, Polpharma, and GSK collectively expanded packaging or API capacity during 2024, positioning the country as Central Europe’s logistics gateway.

The United Kingdom, France, Spain, and Italy jointly contribute 35-40% of the Europe pharmaceutical packaging market. The United Kingdom will maintain EU-equivalent serialization codes post-Brexit, ensuring cross-border packaging compatibility. France tightens biologic-stability testing, which drives Type I borosilicate demand, while Italy pilots outcomes-linked payment contracts that rely on NFC-enabled adherence data to facilitate reimbursement releases. Remaining Northern and Eastern European markets grow at roughly the regional average, with generic-dominant portfolios favoring cost-effective plastic blisters.

Regulatory Landscape

Pharmaceutical packaging in Europe is primarily shaped by two EU-wide regimes: the Falsified Medicines Directive safety-features framework (implemented via Commission Delegated Regulation (EU) 2016/161) and the new Packaging and Packaging Waste Regulation (PPWR), Regulation (EU) 2025/40. PPWR entered into force on 11 February 2025 and applies from 12 August 2026, so packaging placed on the EU market after that date must meet its sustainability-related requirements, while packs placed before can remain in circulation.

Beyond material and waste requirements, compliance extends to labeling and traceability. PPWR adds harmonized labeling provisions, including material-composition sorting labels, tied to implementing acts, while the safety-features framework continues to require unique identifiers and anti-tampering devices on prescription packs. In parallel, the European Medicines Agency and EU institutions are advancing reform of EU pharmaceutical legislation, with adoption targeted in 2026 and phased implementation across 2026-2028, which adds change-management work for artwork, labeling control, and pack approval workflows.

Value Chain Analysis

The value chain begins with regulated raw materials (Type I borosilicate glass, cyclic olefin polymers, pharma-grade PET/HDPE, aluminum foils, papers, and specialty adhesives/inks), followed by conversion into primary components (vials, cartridges, prefillable systems, blisters, bottles, closures) under ISO 15378-aligned quality systems and EU-GMP expectations. Midstream activities include sterilization, ready-to-use (RTU) preparation, and assembly, while secondary and tertiary conversion (cartons, labels, inserts, corrugated) integrates serialization and tamper evidence to satisfy the safety-features requirements under Regulation (EU) 2016/161.

Downstream, contract packaging organizations, CDMOs, and logistics providers connect packaging output to fill-finish plants, wholesalers, and, increasingly, direct-to-patient channels that require GDP-compliant cold-chain performance for biologics. Recent capacity and capability moves show where value is concentrating: Sharp invested more than EUR 20 million to expand injectable packaging capacity in Belgium and the Netherlands, including cold-chain warehousing and syringe assembly, Aenova commissioned an automated tube-packaging line in Germany that raised capacity above 50 million tubes per year, and Woodberry acquired UK folding-carton suppliers Medica Packaging and F.G. Curtis. These actions reflect ongoing investment in automation, local-for-local capacity, and secondary and tertiary scale to handle serialization, aggregation, and upcoming PPWR-driven packaging changes.

Market Opportunities and Future Outlook

PPWR application from 12 August 2026 creates a clear commercialization window for packaging redesign programs that preserve medicine protection while improving recyclability, labeling harmonization, and secondary and tertiary material efficiency. Converters and material suppliers that can qualify medical-grade recycled content for non-contact layers, while maintaining ISO 15378 process validation and pharma change-control requirements, can participate in EU-wide rollouts as brand owners standardize pack formats across countries rather than managing fragmented national approaches.

The ongoing shift toward biologics, injectables, and home administration continues to move spend toward RTU and ready-to-fill primary containers and GDP-ready distribution packs, and the supply chain is already adding capacity for this mix. Sharp’s EUR 20 million expansion in Belgium and the Netherlands, focused on injectables packaging and cold-chain storage, and Adare Pharma Solutions’ 2,800 square meter packaging and warehousing expansion at Pessano (Milan), authorized by AIFA in October 2025, show how manufacturers are aligning packaging and distribution capacity. Anti-counterfeiting and patient-engagement requirements also keep pull-through demand for serialized and NFC-enabled secondary packaging, with opportunities centered on integrated solutions that combine compliant artwork management, tamper evidence, and digital authentication at scale.